Structure Therapeutics (GPCR) Preferred Stock Liabilities (2022)

Structure Therapeutics' (GPCR) quarterly Preferred Stock Liabilities came in at $200.0 million in Q4 2022.

Structure Therapeutics (GPCR) Preferred Stock Liabilities (2022) Analysis & Trends

Structure Therapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $200.0 million for Q4 2022.

On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $200.0 million in Q4 2022; TTM through Dec 2022 was $200.0 million, a N/A change from a year earlier, with the FY2022 full-year figure at $200.0 million, changed N/A from the prior year.
Preferred Stock Liabilities steadied at $200.0 million in Q4 2022 per GPCR's latest filing.
Across five years, Preferred Stock Liabilities topped out at $200.0 million in Q4 2022 and bottomed at $200.0 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Structure Therapeutics	11.04 Bn	11.04 Bn	-	-

Download Data

Date	Value
Dec 31, 2022	199.98 Mn